X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA UNICHEM LAB ELDER PHARMA/
UNICHEM LAB
 
P/E (TTM) x -0.2 -279.1 - View Chart
P/BV x 0.1 2.1 4.9% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 ELDER PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
UNICHEM LAB
Mar-17
ELDER PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs380320 118.8%   
Low Rs188221 85.1%   
Sales per share (Unadj.) Rs491.2167.2 293.8%  
Earnings per share (Unadj.) Rs-3.212.0 -26.6%  
Cash flow per share (Unadj.) Rs14.416.9 85.1%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs376.5117.0 321.7%  
Shares outstanding (eoy) m20.5490.88 22.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.6 35.7%   
Avg P/E ratio x-89.322.6 -394.7%  
P/CF ratio (eoy) x19.716.0 123.4%  
Price / Book Value ratio x0.82.3 32.6%  
Dividend payout %025.1 0.0%   
Avg Mkt Cap Rs m5,83324,578 23.7%   
No. of employees `000NA5.2 0.0%   
Total wages/salary Rs m2,1792,487 87.6%   
Avg. sales/employee Rs ThNM2,928.3-  
Avg. wages/employee Rs ThNM479.4-  
Avg. net profit/employee Rs ThNM209.4-  
INCOME DATA
Net Sales Rs m10,08915,195 66.4%  
Other income Rs m257110 232.8%   
Total revenues Rs m10,34615,305 67.6%   
Gross profit Rs m-7921,788 -44.3%  
Depreciation Rs m361452 80.0%   
Interest Rs m2,75634 8,178.9%   
Profit before tax Rs m-3,6531,413 -258.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125326 38.4%   
Profit after tax Rs m-651,087 -6.0%  
Gross profit margin %-7.811.8 -66.7%  
Effective tax rate %-3.423.1 -14.9%   
Net profit margin %-0.67.2 -9.1%  
BALANCE SHEET DATA
Current assets Rs m9,2406,426 143.8%   
Current liabilities Rs m9,9983,917 255.2%   
Net working cap to sales %-7.516.5 -45.5%  
Current ratio x0.91.6 56.3%  
Inventory Days Days4668 68.4%  
Debtors Days Days6077 77.9%  
Net fixed assets Rs m10,1247,410 136.6%   
Share capital Rs m206182 113.1%   
"Free" reserves Rs m5,58210,454 53.4%   
Net worth Rs m7,73410,636 72.7%   
Long term debt Rs m4,8894 111,113.6%   
Total assets Rs m22,88215,258 150.0%  
Interest coverage x-0.342.9 -0.8%   
Debt to equity ratio x0.60 152,819.1%  
Sales to assets ratio x0.41.0 44.3%   
Return on assets %11.87.3 160.1%  
Return on equity %-0.810.2 -8.3%  
Return on capital %22.313.6 164.1%  
Exports to sales %3.024.1 12.6%   
Imports to sales %0.44.9 8.6%   
Exports (fob) Rs m3073,666 8.4%   
Imports (cif) Rs m43752 5.7%   
Fx inflow Rs m3075,298 5.8%   
Fx outflow Rs m1250-   
Net fx Rs m1815,298 3.4%   
CASH FLOW
From Operations Rs m11,754683 1,719.9%  
From Investments Rs m-561-1,316 42.6%  
From Financial Activity Rs m-6,762592 -1,141.8%  
Net Cashflow Rs m4,432-40 -11,107.0%  

Share Holding

Indian Promoters % 39.6 50.1 79.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 15.1 49.7%  
FIIs % 16.8 3.0 560.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 31.7 113.9%  
Shareholders   16,479 20,176 81.7%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PLETHICO PHARMA  BIOCON LTD  ALEMBIC LTD  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS